# US 2016/0354403 A1 · Endothelial cell genes and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354403 A1
- Document ID: US20160354403A1
- Status: Published application
- Kind: A1
- Application number: 14/903,899
- Filed: 2014-07-09
- Published: 2016-12-08
- Earliest claimed: 2013-07-09
- Assignees: President and Fellows of Harvard College; The Brigham and Women's Hospital, Inc.
- Applicants: President and Fellows of Harvard College; The Brigham and Women's Hospital, Inc.
- Inventors: Ulrich H. von Andrian; Aude Thiriot; Omid Farokhzad; Jinjun Shi
- Web page: https://patentgrep.com/patent/US20160354403A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- C07K 14/47: from mammals
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are genes which are differentially expressed in venule endothelial cells (V-ECs) compared to non-venule endothelial cells (NV-ECs) and methods, compositions, kits, and agents relating to those genes.

## Claims

### Claim 1

A method of modulating the venuleness of an endothelial cell, comprising contacting the endothelial cell with an effective amount of an agent that modulates expression of at least one gene that is differentially expressed in venule endothelial cells compared to non-venule endothelial cells.

### Claim 2 (depends on 1)

A method according to claim 1, wherein modulating the venuleness of the endothelial cell comprises changing the endothelial cell from a venule endothelial cell to a non-venule endothelial cell.

### Claim at position 3

-7. (canceled)

### Claim 8 (depends on 1)

A method according to claim 1, wherein modulating the venuleness of the endothelial cell comprises changing the endothelial cell from a non-venule endothelial cell to a venule endothelial cell.

### Claim at position 5

-13. (canceled)

### Claim 14 (depends on 1)

A method according to claim 1, wherein the venuleness of the endothelial cells is modulated in a tissue-specific manner.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the endothelial cell is a skin endothelial cell, an adipose tissue endothelial cell, or a lymph node endothelial cell.

### Claim at position 8

-53. (canceled)

### Claim 54 (depends on 2)

A method according to claim 2, wherein changing the endothelial cell from a venule endothelial cell to a non-venule endothelial cell interferes with leukocyte interactions with the endothelial cell, or
wherein changing the endothelial cell from a venule endothelial cell to a non-venule endothelial cell interferes with extravasation of leukocytes to the extravascular compartment in the tissue in which the endothelial cell resides, or
wherein changing the endothelial cell from a venule endothelial cell to non-venule endothelial cell decreases a local inflammatory response in the tissue in which the endothelial cell resides.

### Claim at position 10

-56. (canceled)

### Claim 57 (depends on 8)

A method according to claim 8, wherein changing the endothelial cell from a non-venule endothelial cell to a venule endothelial cell enables leukocyte interactions with the endothelial cell, or
wherein changing the endothelial cell from a non-venule endothelial cell to a venule endothelial cell enables extravasation of leukocytes to the extravascular compartment in the tissue in which the endothelial cell resides, or
wherein changing the endothelial cell from a non-venule endothelial cell to a venule endothelial cell enables a local inflammatory response in the tissue in which the endothelial cell resides.

### Claim at position 12

-65. (canceled)

### Claim 66 (depends on 1)

A method according to claim 1, wherein the agent is coupled to an endothelial cell targeting agent that binds to a protein expressed on the surface of the endothelial cell.

### Claim at position 14

-171. (canceled)

### Claim 172

A method of targeting an agent to microvessel endothelial cells in a subject, comprising administering to the subject a therapeutically effective amount of an agent to be targeted to microvessel endothelial cells, wherein the agent is coupled to a microvessel endothelial cell targeting agent.

### Claim 173 (depends on 172)

A method according to claim 172, wherein the microvessel endothelial cell targeting agent binds to a protein expressed on the surface of a microvessel endothelial cell.

### Claim 174 (depends on 173)

A method according to claim 173, wherein the protein is encoded by a gene exhibiting higher expression levels in venule endothelial cells compared to non-venule endothelial cells, or
wherein the protein is encoded by a gene exhibiting higher expression levels in non-venule endothelial cells compared to venule endothelial cells.

### Claim at position 18

-204. (canceled)

### Claim 205 (depends on 172)

A method according to claim 172, wherein the microvessel endothelial cell targeting agent is internalized into the endothelial cells lining the microvessel.

### Claim 206 (depends on 205)

A method according to claim 205, wherein internalization of the microvessel endothelial cell targeting agent into the endothelial cells lining the microvessel causes the microvessel endothelial cell targeting agent to accumulate in the tissue in which the microvessel resides.

### Claim at position 21

-226. (canceled)

### Claim 227 (depends on 172)

A method according to claim 172, wherein targeting an agent to microvessel endothelial cells of the subject treats, prevents, or ameliorates a symptom of, an inflammatory disease in the subject.

### Claim at position 23

-309. (canceled)

### Claim 310

A method of identifying a candidate agent that modulates the venuleness of an endothelial cell, comprising:
(a) contacting an endothelial cell or a population of endothelial cells with a test agent;
(b) detecting expression levels in the endothelial cell or the population of endothelial cells, in the presence of the test agent, of at least one gene which is differentially expressed in venule endothelial cells compared to non-venule endothelial cells; and
(c) identifying a candidate agent that modulates the venuleness of an endothelial cell, wherein:
(i) the test agent is a candidate agent that induces endothelial cells to become venule endothelial cells if, in the presence of the test agent, the endothelial cell or the population of endothelial cells exhibit elevated levels of expression of at least one gene exhibiting higher expression levels in venule endothelial cells compared to non-venule endothelial cells;
(ii) the test agent is a candidate agent that induces endothelial cells to become venule endothelial cells if, in the presence of the test agent, the endothelial cell or the population of endothelial cells exhibit reduced levels of expression of at least one gene exhibiting lower expression levels in venule endothelial cells compared to non-venule endothelial cells;
(iii) the test agent is a candidate agent that induces endothelial cells to become non-venule endothelial cells if, in the presence of the test agent, the endothelial cell or the population of endothelial cells exhibit elevated levels of expression of at least one gene exhibiting higher expression levels in non-venule endothelial cells compared to venule endothelial cells; or
(iv) the test agent is a candidate agent that induces endothelial cells to become non-venule endothelial cells if, in the presence of the test agent, the endothelial cell or the population of endothelial cells exhibit reduced levels of expression of at least one gene exhibiting lower expression levels in non-venule endothelial cells compared to venule endothelial cells.

### Claim at position 25

-314. (canceled)

### Claim 315 (depends on 310)

A method according to claim 310, wherein the at least one gene is differentially expressed in skin venule endothelial cells compared to skin non-venule endothelial cells, or
wherein the at least one gene is differentially expressed in adipose tissue venule endothelial cells compared to adipose tissue non-venule endothelial cells, or
wherein the at least one gene is differentially expressed in lymph node venule endothelial cells compared to lymph node non-venule endothelial cells.

### Claim at position 27

-330. (canceled)

### Claim 331 (depends on 310)

A method according to claim 310, wherein the endothelial cell or the population of endothelial cells are obtained from an in vitro source or from an in vivo source.

### Claim at position 29

-349. (canceled)

### Claim 350 (depends on 310)

A method according to claim 310, further comprising sorting the venule and non-venule endothelial cells.

### Claim at position 31

-355. (canceled)

### Claim 356 (depends on 310)

A method according to claim 310, further comprising assessing the ability of the candidate agent to exhibit an anti-inflammatory effect.

### Claim at position 33

-359. (canceled)

### Claim 360 (depends on 310)

A method according to claim 310, further comprising coupling the candidate agent to an endothelial cell targeting agent that binds to a protein expressed on the surface of an endothelial cell, and assessing the ability of the endothelial cell targeting agent to target the candidate agent to a targeted tissue comprising the endothelial cell.

### Claim at position 35

-382. (canceled)

### Claim 383

A method of modulating leukocyte trafficking and/or inflammation in a subject in need thereof, comprising: (a) administering to the subject an effective amount of an agent that modulates expression of at least one gene which is differentially expressed in venule endothelial cells compared to non-venule endothelial cells, and (b) modulating leukocyte trafficking and/or inflammation in the subject, wherein: (i) an agent that decreases expression of at least one gene which exhibits higher expression levels in venule endothelial cells compared to non-venule endothelial cells inhibits leukocyte trafficking and/or inflammation in the subject; (ii) an agent that increases expression of at least one gene which exhibits lower expression levels in venule endothelial cells compared to non-venule endothelial cells inhibits leukocyte trafficking and/or inflammation in the subject; (iii) an agent that decreases expression of at least one gene which exhibits higher expression levels in non-venule endothelial cells compared to venule endothelial cells enables leukocyte trafficking and/or inflammation to be induced in the subject; or (iv) an agent that increases expression of at least one gene which exhibits lower expression levels in non-venule endothelial cells compared to venule endothelial cells enables leukocyte trafficking and/or inflammation to be induced in the subject.

### Claim at position 37

-387. (canceled)

### Claim 388 (depends on 383)

A method according to claim 383, wherein the at least one gene is differentially expressed in skin venule endothelial cells compared to skin non-venule endothelial cells, or
wherein the at least one gene is differentially expressed in adipose tissue venule endothelial cells compared to adipose tissue non-venule endothelial cells, or
wherein the at least one gene is differentially expressed in lymph node venule endothelial cells compared to lymph node non-venule endothelial cells.

### Claim at position 39

-403. (canceled)

### Claim 404 (depends on 383)

A method according to claim 383, wherein inhibiting leukocyte trafficking and/or inflammation comprises one or more of interfering with leukocyte trafficking, interfering with leukocyte adhesion, and interfering with leukocyte extravasation, or
wherein enabling leukocyte trafficking and/or inflammation to be induced comprises one or more of enabling leukocyte trafficking, enabling leukocyte adhesion, and enabling leukocyte extravasation.

### Claim at position 41

-832. (canceled)
